BELLUS Health Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BLU research report →
Range $14.75 – $14.75
Price Chart
About the company
BELLUS Health Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to creating new therapeutic options for intractable chronic cough (RCC) and various other conditions characterized by heightened cough sensitivity. The company's primary investigational compound, BLU-5937, functions as a P2X3 receptor antagonist.
- CEO
- Roberto Francesco Bellini
- IPO
- 2000
- Employees
- 74
- HQ
- Laval, QC, CA
Get TickerSpark's AI analysis on BLU
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.87B
- P/E
- -20.58
- PEG
- -2.01
- P/S
- 107657.12
- P/B
- 4.01
- EV/EBITDA
- -21.64
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -486768.75%
- Net Margin
- -475500.00%
- ROE
- -22.28%
- ROIC
- -19.85%
Latest fiscal year · YoY change
- Revenue
- $16.00K+0.0%
- Gross Profit
- $-3,514,736,653-58.2%
- Op Income
- $-77,883,000
- Net Income
- $-76,080,000-6.8%
- EPS
- $-0.66+26.7%
- OCF Growth
- -25.9%
- FCF Growth
- -41.0%
- 52W High
- $14.76
- 52W Low
- $6.38
- 50D MA
- $14.40
- 200D MA
- $10.11
- Beta
- -0.28
- RSI (14)
- 79
- Avg Volume
- 5.38M
No earnings-call transcripts are available for BLU yet.
- Free Float
- 72.7%
- Shares Outstanding
- 126.81M
- Float Shares
- 92.13M
of shares held by institutions
12 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Pendal Group Ltd | 127.57K | ▲ 99.24K |
Our BLU coverage
Recent articles, reports, and earnings notes.
No research on BLU yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BLU report →BLUENERGIES ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT OF UNITS FOR GROSS PROCEEDS OF C$20.7 MILLION
prnewswire.com · Jul 23
Bellus Health shareholders say yes to US$2B GSK takeover
proactiveinvestors.com · Jun 19
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders
businesswire.com · Jun 16
Alliance Entertainment Reports Third Quarter and Nine Month Fiscal 2023 Financial Results
businesswire.com · May 22
BELLUS Santé inc. convoque une assemblée extraordinaire des actionnaires concernant l’acquisition de la société par GSK
businesswire.com · May 16
BELLUS Health Inc. Calls Special Shareholders' Meeting in Connection with GSK Acquisition
businesswire.com · May 16
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights
businesswire.com · May 12
BELLUS Santé annonce ses résultats financiers et faits saillants pour le premier trimestre de 2023
businesswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.